Literature DB >> 17685384

Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option.

Gregory W Allen1, Andrew R Howard, David F Jarrard, Mark A Ritter.   

Abstract

Depending on initial prognostic factors, an estimated 10%-60% of men who undergo definitive radiation therapy for prostate cancer may experience a biochemical recurrence. Even though hormonal therapy is standard for metastatic recurrences, no consensus exists on optimal salvage therapy for those recurrences thought confined to the prostate. Salvage treatment options for these local recurrences have historically been limited to salvage prostatectomy, hormonal therapy, or cryotherapy. Salvage prostate brachytherapy, however, uses a widely available technique and may provide another option for attaining disease control in patients with localized failures, although only about 110 cases have been reported in the literature. In this report, the authors have described their own series of salvage brachytherapy cases as well as presented a review of other such series reported in the literature. In addition, the authors included a comprehensive review of published experiences with surgery and cryotherapy as salvage options. It appears that salvage brachytherapy, when combined with careful patient selection, is at least as effective as other salvage options with comparable or potentially fewer treatment-related side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17685384     DOI: 10.1002/cncr.22940

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.

Authors:  Xuehong Deng; Han Liu; Jiaoti Huang; Liang Cheng; Evan T Keller; Sarah J Parsons; Chang-Deng Hu
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 2.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

Review 3.  Re-irradiation for salvage of prostate cancer failures after primary radiotherapy.

Authors:  Stephen J Ramey; David T Marshall
Journal:  World J Urol       Date:  2012-09-28       Impact factor: 4.226

4.  Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.

Authors:  M Kamrava; A H Kesarwala; R A Madan; E Lita; A Kaushal; K-Y Tsang; D J Poole; S M Steinberg; T Ferrara; W Dahut; J Schlom; J L Gulley
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-03-06       Impact factor: 5.554

5.  Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy.

Authors:  G Lahmer; M Lotter; S Kreppner; R Fietkau; V Strnad
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621

6.  Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy.

Authors:  Patrick A Kenney; Cayce B Nawaf; Mahmoud Mustafa; Sijin Wen; Matthew F Wszolek; Curtis A Pettaway; John F Ward; John W Davis; Louis L Pisters
Journal:  Can J Urol       Date:  2016-06       Impact factor: 1.344

7.  Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry.

Authors:  Philippe E Spiess; David A Levy; Louis L Pisters; Vladimir Mouraviev; J Stephen Jones
Journal:  World J Urol       Date:  2012-11-23       Impact factor: 4.226

Review 8.  Targeted radiotherapy with gold nanoparticles: current status and future perspectives.

Authors:  Wilfred Ngwa; Rajiv Kumar; Srinivas Sridhar; Houari Korideck; Piotr Zygmanski; Robert A Cormack; Ross Berbeco; G Mike Makrigiorgos
Journal:  Nanomedicine (Lond)       Date:  2014-05       Impact factor: 5.307

9.  mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.

Authors:  Matthew J Schiewer; Robert Den; David T Hoang; Michael A Augello; Yaacov R Lawrence; Adam P Dicker; Karen E Knudsen
Journal:  Endocr Relat Cancer       Date:  2012-01-09       Impact factor: 5.678

10.  M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer.

Authors:  Xiaoyi Huang; Fang Yuan; Meihua Liang; Hui-Wen Lo; Mari L Shinohara; Cary Robertson; Pei Zhong
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.